'Transformational' quarter at Wockhardt as debt woes set to ease
This article was originally published in Scrip
Buoyed with funds from the recently concluded sale of its nutrition business to Danone for Rs12.80 billion ($229.6 million) and a strong set of numbers for the first quarter ended 30 June, the financially-stretched Wockhardt expects to prune debt significantly and exit the corporate debt restructuring (CDR) process.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.